Current prediction models for risk of cardiovascular
disease (CVD) incidence incorporate
smoking as a dichotomous yes/no measure.
However, the risk of CVD associated with
smoking also varies with the intensity and
duration of smoking and there is a strong
association between time since quitting and the risk of disease onset. This study aims to
develop improved risk prediction equations for
CVD incidence incorporating intensity and
duration of smoking and time since quitting.
The risk of developing a first CVD event was
evaluated using a Cox’s model for participants
in the Framingham offspring cohort who
attended the fourth examination (1988-92)
between the ages of 30 and 74 years and were
free of CVD (n=3751). The full models based
on the smoking variables and other risk factors,
and reduced models based on the smoking
variables and non-laboratory risk factors
demonstrated good discrimination, calibration
and global fit. The incorporation of both time
since quitting among past smokers and packyears
among current smokers resulted in better
predictive performance as compared to a
dichotomous current/non-smoker measure
and a current/quitter/never smoker measure.
Compared to never smokers, the risk of CVD
incidence increased with pack-years. Risk
among those quitting more than five years
prior to the baseline exam and within five
years prior to the baseline exam were similar
and twice as high as that of never smokers. A
CVD risk equation incorporating the effects of
pack-years and time since quitting provides an
improved tool to quantify risk and guide preventive
care.
Coronary heart disease, predictive equation, detailed smoking measures, other risk factors, reduced equation.
Haider Mannan, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Centre, 99 Commercial Road, Melbourne 3004, Victoria, Australia. E-mail: haider.mannan@monash.edu
The Framingham Heart Study –
Offspring (FHS-O) is conducted and supported by
the NHLBI in collaboration with the FHS-O Study
Investigators. This manuscript was prepared
using a limited access dataset obtained from the
NHLBI and does not necessarily reflect the opinions
or views of the FHS-O or the NHLBI. This
research was supported by an NHMRC health
services research grant (n. 465130), an
NHMRC/NHF PhD scholarship and a Vichealth
Fellowship.
2010-07-06
Trending Topic
This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]
Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 ...
Summary Few clinical studies have shown an association between coronary artery disease (CAD) and osteoporosis. This cross-sectional study has shown that, among Indian postmenopausal women, the prevalence of CAD increases across lower bone mineral density categories. Femoral neck osteoporosis confers ...
Glucagon-like peptide 1 (GLP-1) receptor agonists piqued our interest when Marso et al. demonstrated that liraglutide significantly reduced cardiovascular events (CVEs) in persons with type 2 diabetes mellitus (T2DM) who were at a high cardiovascular (CV) risk compared with placebo in ...
Over the past two decades, the field of transcatheter aortic valve replacement (TAVR) has experienced remarkable advancement. Initially approved for patients with high and prohibitive surgical risk, TAVR has progressively extended its indications to all patients, regardless of surgical risk. ...
Cardiovascular disease (CVD) continues to be the leading cause of death on a global scale. Nearly 18 million people died from CVD in 2019, accounting for about one-third of all deaths globally.1 The primary cause of CVD-related death and morbidity is ischaemic ...
With the global increase in life expectancy, the proportion of elderly people in the community is expected to increase gradually. This is referred to as the 'Coming of the Gray Dawn' or the 'Gray Wave', and highlights the need for ...
Cardiac complications constitute a common cause of morbidity and mortality in the perioperative period, contributing to over a third of perioperative deaths.1 More than 230 million major surgeries are performed annually worldwide, with older patients representing an increasing proportion of the ...
Diabetes mellitus (DM) is strongly associated with severe macro- and micro-vascular complications; it is also proven to be a strong independent risk factor for developing heart failure (HF).1 In fact, the prevalence of DM is reported to be as high ...
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality both in the US and worldwide.1 There is substantial evidence from genetic, observational and interventional studies that low-density lipoprotein cholesterol (LDL-C) is causally related to the development of ASCVD in ...
The prevalence of aortic stenosis (AS) has grown over the last few decades, as life expectancy has increased. AS is the most common valvular disease in the developed world and is found in up to 9.8% of individuals aged ≥75.1–3 The wide ...
Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease affecting 1 in 500 individuals worldwide.1 The disease pathogenesis of HCM is characterized by hypertrophy and myocyte disarray, along with muscle fibrosis on histopathology and intramural hyperplasia of the coronary arteries.2 HCM is diagnosed ...
The systemic amyloidoses are a group of heterogenous diseases, which are characterized by the deposition of insoluble amyloid fibrils within the extracellular matrix of multiple organs throughout the body. Amyloid fibrils are formed from the misfolding of amyloid precursor proteins (...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.